New York, Feb 27, 2026, 09:24 EST — Premarket
- 10x Genomics shares pointed 3.3% lower before the bell.
- Recent regulatory filings show both CEO Serge Saxonov and CFO Adam Taich have sold shares.
- Investors are eyeing the March 3 management appearance, hoping for new clues on demand.
10x Genomics shares dropped roughly 3.3% to $21.40 ahead of Friday’s open, giving back some ground after a late-session dip that followed a big rally the session before. Thursday’s close landed at $22.13, a 12.6% gain.
Insider activity is again in focus, with the stock moving sharply despite little in the way of fresh headlines or clear positioning shifts.
All this happens just days ahead of the company’s next public appearance—another moment traders will watch to see if the rally sticks or unravels.
Adam Taich, the company’s Chief Financial Officer, offloaded 8,968 shares on Feb. 23 at an average price of $18.5764, according to a regulatory filing. The document noted the sale was made to handle tax withholding requirements from vested restricted stock units.
Serge Saxonov, the Chief Executive Officer, unloaded 9,632 shares that day at the same average price, a separate filing shows. The disclosure cites tax withholding related to vesting, mirroring the earlier explanation.
Sales like these often pop up near vesting dates. Yet, when the stock has just delivered a standout daily surge, they can put a dent in sentiment.
10x Genomics posted quarterly revenue of $166.0 million earlier this month, wrapping up 2025 with $523.4 million on hand across cash, cash equivalents, and marketable securities. Looking ahead, the company is projecting 2026 revenue between $600 million and $625 million. Saxonov noted 10x navigated “with discipline through a challenging environment.”
Still, 10x is vulnerable to ups and downs in lab budgets. If customers start holding off on major buys, that tends to hit orders and guidance almost immediately.
Investors are eyeing March 3, when management sits down for a fireside chat at TD Cowen’s annual health care conference. They’ll be hunting for any fresh details on demand and how quickly instruments are being placed.
